HeartMate II thrombosis treated without explantation in the waiting period for heart transplantation: a case report.
Case report
Heart transplantation
LVAD thrombosis
Journal
European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
09
05
2020
revised:
16
06
2020
accepted:
24
11
2020
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
19
2
2021
Statut:
epublish
Résumé
The HeartMate II (HMII) is a high speed, axial flow, rotary blood pump that restores systemic flow by draining blood from the left ventricular (LV) apex and ejecting into the aortic root. This LV assist device was previously used in patients with medically refractory advanced-stage heart failure, for both destination therapy and bridge to transplantation until the introduction of HeartMate III. We report herein a case of a 25-year-old patient with Interagency Registry for Mechanical Assisted circulatory 3 profile implanted with HMII device for an end-stage dilated cardiomyopathy, who experienced a pump thrombosis despite a well-conducted anticoagulant protocol. A thrombophilia with heterozygous mutation of factor II and V was diagnosed at that time. We chose to stop the device without explantation until heart transplantation. Pump thrombosis with HMII is associated with a prohibitive risk of morbidity and mortality. Pump thrombosis is suspected when haemolysis or congestive heart failure occurs, also in cases of overconsumption of pump power (>10 W). Pump thrombosis treatment is challenging in the case of clotting factors mutation. Pump exchange could be ineffective, exposing the patient to the recurrence of thrombo-embolic events. Intravenous thrombolysis may be used for patients not candidates for redo procedures but could be unsuccessful and expose patients to high bleeding risk. Heart transplantation remains a reliable option. In our case, pump explantation was considered too hazardous by the heart team due to a prohibitive risk of redo surgery. Then, we decided to turn off the HMII pump after the introduction of continuous intravenous dobutamine support. The haemodynamic stability allowed us to wait for heart transplantation in favourable conditions.
Sections du résumé
BACKGROUND
BACKGROUND
The HeartMate II (HMII) is a high speed, axial flow, rotary blood pump that restores systemic flow by draining blood from the left ventricular (LV) apex and ejecting into the aortic root. This LV assist device was previously used in patients with medically refractory advanced-stage heart failure, for both destination therapy and bridge to transplantation until the introduction of HeartMate III.
CASE SUMMARY
METHODS
We report herein a case of a 25-year-old patient with Interagency Registry for Mechanical Assisted circulatory 3 profile implanted with HMII device for an end-stage dilated cardiomyopathy, who experienced a pump thrombosis despite a well-conducted anticoagulant protocol. A thrombophilia with heterozygous mutation of factor II and V was diagnosed at that time. We chose to stop the device without explantation until heart transplantation.
DISCUSSION
CONCLUSIONS
Pump thrombosis with HMII is associated with a prohibitive risk of morbidity and mortality. Pump thrombosis is suspected when haemolysis or congestive heart failure occurs, also in cases of overconsumption of pump power (>10 W). Pump thrombosis treatment is challenging in the case of clotting factors mutation. Pump exchange could be ineffective, exposing the patient to the recurrence of thrombo-embolic events. Intravenous thrombolysis may be used for patients not candidates for redo procedures but could be unsuccessful and expose patients to high bleeding risk. Heart transplantation remains a reliable option. In our case, pump explantation was considered too hazardous by the heart team due to a prohibitive risk of redo surgery. Then, we decided to turn off the HMII pump after the introduction of continuous intravenous dobutamine support. The haemodynamic stability allowed us to wait for heart transplantation in favourable conditions.
Identifiants
pubmed: 33598606
doi: 10.1093/ehjcr/ytaa509
pii: ytaa509
pmc: PMC7873806
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ytaa509Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Eur J Cardiothorac Surg. 2015 Jun;47(6):984-9
pubmed: 25209626
N Engl J Med. 2009 Dec 03;361(23):2241-51
pubmed: 19920051
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
N Engl J Med. 2019 Apr 25;380(17):1618-1627
pubmed: 30883052
N Engl J Med. 2014 Apr 10;370(15):1464
pubmed: 24716696
J Heart Lung Transplant. 2013 Jul;32(7):667-70
pubmed: 23796150
N Engl J Med. 2014 Jan 2;370(1):33-40
pubmed: 24283197
J Heart Lung Transplant. 2017 Jan;36(1):1-12
pubmed: 27865732